Table 2.
Summary of clinical trial after osimertinib resistance
| Agent | Trial number (Trial name) | Phase | Number of patients | Arm | Year | Status |
|---|---|---|---|---|---|---|
| Fourth-generation EGFR allosteric inhibitor | ||||||
| BLU-701 | NCT05153408 (HARMONY) | I/II | 160 | BLU-701 BLU-701 + osimertinib BLU-701 + CBDCA + PEM |
2021 | Recruiting |
| BLU-945 | NCT04862780 (SYMPHONY) | I/II | 190 | BLU-945 BLU-945 + osimertinib |
2021 | Recruiting |
| BBT-176 | NCT04820023 | I/II | 168 | BBT-176 | 2021 | Recruiting |
| JIN-A02 | NCT05394831 | I/II | 95 | JIN-A02 | 2022 | Not yet recruiting |
| MET inhibitor | ||||||
| Savolitinib | NCT02143466 (TATTON) | Ib | 344 | Savolitinib + osimertinib | 2014 | Active, not recruiting |
| NCT03778229 (SAVANNAH) | II | 360 | Savolitinib + osimertinib Sabolitinib + placebo |
2018 | Recruiting | |
| NCT05015608 (SACHI) | III | 250 | Savolitinib + osimertinib CDDP/CBDCA + PEM |
2021 | Recruiting | |
| NCT05261399 (SAFFRON) | III | 324 | Savolitinib + osimertinib CDDP/CBDCA + PEM |
2022 | Recruiting | |
| Tepotinib | NCT03940703 (INSIGHT2) | II | 120 | Tepotinib + osimertinib Tepotinib |
2019 | Active, not recruiting |
| Capmatinib | NCT05642572 (A Lung-MAP) | II | 66 | Capmatinib + osimertinib + ramucirumab Capmatinib + osimertinib |
2022 | Not yet recruiting |
| NCT04816214 (GEOMETRY-E) | III | 245 | Capmatinib + osimertinib CDDP/CBDCA + PEM |
2021 | Active, not recruiting | |
| Other specific inhibitor | ||||||
| Selumetinib (MEK1/2 inhibitor) | NCT02143466 (TATTON) | Ib | 344 | Selumetinib + osimertinib | 2014 | Active, not recruiting |
| DS-1205c (AXL inhibitor) | NCT03255083 | I | 13 | DS-1205c + osimertinib | 2017 | Terminated |
| ERAS-007 (ERK1/2 inhibitor) | NCT04959981 (HERKULES-2) | I/II | 200 | ERAS-601 + osimertinib | 2021 | Active, not recruiting |
| Sapanisertib (mTOR inhibitor) | NCT02503722 | I | 36 | Sapanisertib + osimertinib | 2015 | Active, not recruiting |
| TQ-B3525 (PIKα/δ inhibitor) | NCT05284994 | I/II | 160 | TQ-B3525 + osimetinib | 2022 | Recruiting |
| Itacitinib (JAK1 inhibitor) | NCT02917993 | I/II | 59 | Itacitinib + osimertinib | 2016 | Active, not recruiting |
| Abemaciclib (CDK4/6 inhibitor) | NCT04545710 | II | 18 | Abemaciclib + osimetinib | 2020 | Recruiting |
| Alisertib (AURKA inhibitor) | NCT04479306 | I | 48 | Alisertib + osimetinib | 2020 | Active, not recruiting |
| Antibody–drug conjugate | ||||||
| Trastuzumab deruxtecan (T-Dxd) (HER2-ADC) | NCT04042701 | Ib | 115 | T-DXd + pembrolizumab (part 2 dose expansion cohort) |
2019 | Recruiting |
| Patritumab deruxtecan (HER3-ADC) | NCT03260491 | I | 264 | HER3-DXd | 2017 | Recruiting |
| NCT04676477 | I | 252 | HER3-DXd + osimertinib | 2020 | Recruiting | |
| NCT04619004 (HERTHENA-Lung01) | II | 420 | HER3-DXd (fixed dose or up-titration) |
2020 | Recruiting | |
| NCT05338970 (HERTHENA-Lung02) | III | 560 | HER3-DXd CDDP/CBDCA + PEM |
2022 | Recruiting | |
(Continued)